The United States Food and Drug Administration (FDA) has approved the remedē System, marketed by ZOLL Medical Corporation, for conditional use with magnetic resonance imaging (MRI). ZOLL’s remedē System is an implantable transvenous phrenic nerve stimulation therapy for the treatment of adults with moderate to severe central sleep apnea. Full-body MRI approval applies to all…
“Not feeling like it.” In the daily pursuit of Christ, I fear no phrase has hindered me more. A few moments’ reflection reminds me of the silliness of such a feelings-based spirituality. A farmer will find nothing at harvest if he sets aside his plow with a wave of “not feeling like it.” A pianist…
Interview by Alyx Arnett Obesity is widely recognized as a major contributor to the development of obstructive sleep apnea (OSA). A 10% increase in weight can multiply the risk of OSA sixfold.1 Weight loss, on the other hand, is often recommended to lessen the condition’s severity. Atul Malhotra, MD While the bidirectional relationship between obesity…
Interview by Alyx Arnett Women with obstructive sleep apnea (OSA) often present with lower apnea-hypopnea indexes (AHI) and fewer oxygen desaturations than men, as well as atypical symptoms like fatigue and insomnia—differences that put them at risk of being underdiagnosed and undertreated.1 Alison Wimms, PhD But despite its subtler appearance, research suggests that the negative…